Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

F

Federal University of São Paulo

Status

Completed

Conditions

Conjunctivitis, Viral
Adenoviridae Infections

Treatments

Drug: Ganciclovir
Drug: Artificial tear

Study type

Interventional

Funder types

Other

Identifiers

NCT01349452
GAN2011

Details and patient eligibility

About

Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

Enrollment

33 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • onset of symptoms for five days or less
  • eighteen years old or more
  • not pregnant or breastfeeding
  • be able to understand and sign the consent term

Exclusion criteria

  • use of antibiotic or corticoid 30 days before
  • monocular vision
  • keratopathy or other ocular diseases

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

33 participants in 2 patient groups

Ganciclovir
Experimental group
Treatment:
Drug: Ganciclovir
Artificial tear
Sham Comparator group
Treatment:
Drug: Artificial tear

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems